Spots Global Cancer Trial Database for A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Official Title: A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
Study ID: NCT05800665
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
HonorHealth, Scottsdale, Arizona, United States
Yale Cancer Center, New Haven, Connecticut, United States
Florida Cancer Specialists & Research Institute - Lake Nona Cancer Center, Orlando, Florida, United States
Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee, United States
St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
Austin Hospital, Heidelberg, Victoria, Australia
Seoul National University Hospital, Seoul, , Korea, Republic of
Asan Medical Center - PPDS, Seoul, , Korea, Republic of
Contact Details
Name: Clinical Trials
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
